Berkeley, CA – According to filings with the U.S. Securities and Exchange Commission, FlightPath Biosciences is raising $5,000,000.00 in new funding. Sources indicate as part of senior management President and Chief Executive Officer, Matthew Tindall played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About FlightPath Biosciences

Flightpath Biosciences, Inc is a biotechnology company developing novel therapeutics for the treatment of tick-borne diseases.

To learn more about FlightPath Biosciences, visit http://flightpath.bio/

Contact:
Matthew Tindall, President and Chief Executive Officer
415-530-1828
matt@flightpath.bio
https://www.linkedin.com/in/matthewtindall/

SOURCE: http://www.intelligence360.io
Copyright (c) 2020 SI360 Inc. All rights reserved